GlaxoSmithKline’s (GSK) Buy Rating Reiterated at Liberum Capital

Liberum Capital reaffirmed their buy rating on shares of GlaxoSmithKline (LON:GSK) in a research report released on Tuesday morning.

Other research analysts have also recently issued research reports about the company. UBS Group set a GBX 1,600 ($20.71) target price on GlaxoSmithKline and gave the company a buy rating in a research note on Friday, May 25th. Jefferies Financial Group set a GBX 1,650 ($21.36) target price on GlaxoSmithKline and gave the company a buy rating in a research note on Monday, May 14th. Berenberg Bank raised their target price on GlaxoSmithKline from GBX 1,780 ($23.04) to GBX 1,790 ($23.17) and gave the company a buy rating in a research note on Wednesday, April 25th. Goldman Sachs Group set a GBX 1,900 ($24.60) target price on GlaxoSmithKline and gave the company a buy rating in a research note on Friday, June 29th. Finally, Barclays set a GBX 1,750 ($22.65) target price on GlaxoSmithKline and gave the company a buy rating in a research note on Tuesday, July 3rd. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of GBX 1,541.74 ($19.96).

GlaxoSmithKline opened at GBX 1,575.60 ($20.40) on Tuesday, according to MarketBeat.com. GlaxoSmithKline has a 52 week low of GBX 1,235.20 ($15.99) and a 52 week high of GBX 1,724.50 ($22.32).



The business also recently disclosed a dividend, which will be paid on Thursday, October 11th. Investors of record on Thursday, August 9th will be given a dividend of GBX 19 ($0.25) per share. This represents a yield of 1.23%. The ex-dividend date of this dividend is Thursday, August 9th.

In related news, insider Philip R. Hampton acquired 2,810 shares of GlaxoSmithKline stock in a transaction that occurred on Wednesday, July 25th. The stock was bought at an average price of GBX 1,557 ($20.16) per share, with a total value of £43,751.70 ($56,636.50). Also, insider David Redfern sold 1,925 shares of the firm’s stock in a transaction that occurred on Tuesday, July 31st. The shares were sold at an average price of GBX 1,575 ($20.39), for a total value of £30,318.75 ($39,247.57).

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Recommended Story: Short Selling Stocks, A Beginner’s Guide

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply